Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report) VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Supernus Pharmaceuticals Stock Down 1.3 %
NASDAQ SUPN opened at $39.48 on Thursday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of 36.90 and a beta of 0.90. The company has a fifty day moving average of $37.29 and a two-hundred day moving average of $34.69.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.29) EPS. Equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.
Analyst Ratings Changes
Get Our Latest Report on Supernus Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares during the period. GAMMA Investing LLC increased its position in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares during the period. Exchange Traded Concepts LLC raised its holdings in shares of Supernus Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after purchasing an additional 560 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Supernus Pharmaceuticals by 0.5% in the 4th quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company’s stock worth $6,236,000 after purchasing an additional 800 shares during the period. Finally, Quartz Partners LLC boosted its stake in shares of Supernus Pharmaceuticals by 3.0% during the fourth quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company’s stock valued at $1,031,000 after purchasing an additional 820 shares in the last quarter.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Featured Articles
- Five stocks we like better than Supernus Pharmaceuticals
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 3 Must-Have ETFs Set to Dominate This Quarter
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Why Invest in 5G? How to Invest in 5G Stocks
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.